Document is current
Any future updates will be listed below
-
Authors
Chauvet, Paul https://orcid.org/0000-0001-6326-9283
Saade, Cynthia
Demaret, Julie
Beauvais, David https://orcid.org/0000-0003-1866-828X
Srour, Micha https://orcid.org/0000-0002-8519-4187
Magro, Leonardo
Coiteux, Valérie
Gazeau, Nicolas
Branche, Nicolas
Roche-Lestienne, Catherine
Fenwarth, Laurène
Fournier, Elise
Mitra, Suman
Damaj, Gandhi https://orcid.org/0000-0002-4689-3882
Yakoub-Agha, Ibrahim
- License Information
-
More Information
Article History
Received: 21 April 2025
Revised: 18 July 2025
Accepted: 12 August 2025
First Online: 21 August 2025
Competing interests
: PC: no conflict of interest related to this study. CS: no conflict of interest related to this study. JD: no conflict of interest related to this study. DB: no conflict of interest related to this study. LM: no conflict of interest related to this study. MS: no conflict of interest related to this study. VC: no conflict of interest related to this study. NG: no conflict of interest related to this study. NB: no conflict of interest related to this study. CRL: no conflict of interest related to this study. LF: no conflict of interest related to this study. EF: no conflict of interest related to this study. GD: no conflict of interest related to this study. IY-A: received honorarium from Gikead/Kite, BMS, Novartis and AstraZeneca.
: All analysis presented here were performed in accordance with the relevant guidelines and regulations. All participants provided written informed consent under ethics committee-approved biobank protocol “CAR-LILLE”(CPP ID-RCB: 2020-A01935-34) in accordance with the Declaration of Helsinki.
